Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma: A possible post transcriptional regulation

Xingang Huang, Katsuyoshi Takata, Yasuharu Sato, Takehiro Tanaka, Kouichi Ichimura, Maiko Tamura, Takashi Oka, Tadashi Yoshino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The CD79 molecule, encoded by the CD79a and CD79b genes, is a signaling unit of the B-cell receptor complex, which transmits signals of B-cell activation, growth, and differentiation. They are B-cell-specific and expressed at most stages of B-cell development. Although plasma cells have been believed to lack these gene products, the regulation of CD79 expression in plasma cells is still controversial. In particular, the regulation of CD79b expression remains unclear. We sought to examine CD79b expression in normal and neoplastic plasma cells by immunohistochemical analysis. Out of the 23 clinical samples and 11 cell lines of plasma cell myeloma (PCM), none of the clinical samples and only 1 of 11 cell lines expressed CD79b immunohistologically, whereas non-neoplastic plasma cells in reactive hyperplastic lymph nodes exhibited loss of CD79b protein expression. This finding is quite different from our previous report on CD79a. Not only immunocytochemistry, but also RT-PCR and Western blot analysis of PCM cell lines gave identical results. Interestingly, we detected mRNA transcripts of CD79b in PCM cell lines, although protein translation was lacking. These findings suggest that expression of CD79b is downregulated in both plasma cells and plasma cell myeloma, and this process is possibly under post transcriptional regulation.

Original languageEnglish
Pages (from-to)122-129
Number of pages8
JournalPathology International
Volume61
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Plasma Cells
Multiple Myeloma
B-Lymphocytes
Down-Regulation
Cell Line
Protein Biosynthesis
Genes
Lymph Nodes
Western Blotting
Immunohistochemistry
Polymerase Chain Reaction
Messenger RNA
Growth
Proteins

Keywords

  • B-cell receptor
  • CD79a
  • CD79b
  • Plasma cell
  • Plasma cell myeloma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma : A possible post transcriptional regulation. / Huang, Xingang; Takata, Katsuyoshi; Sato, Yasuharu; Tanaka, Takehiro; Ichimura, Kouichi; Tamura, Maiko; Oka, Takashi; Yoshino, Tadashi.

In: Pathology International, Vol. 61, No. 3, 03.2011, p. 122-129.

Research output: Contribution to journalArticle

@article{de82d91616624dd7b914cbb156232c46,
title = "Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma: A possible post transcriptional regulation",
abstract = "The CD79 molecule, encoded by the CD79a and CD79b genes, is a signaling unit of the B-cell receptor complex, which transmits signals of B-cell activation, growth, and differentiation. They are B-cell-specific and expressed at most stages of B-cell development. Although plasma cells have been believed to lack these gene products, the regulation of CD79 expression in plasma cells is still controversial. In particular, the regulation of CD79b expression remains unclear. We sought to examine CD79b expression in normal and neoplastic plasma cells by immunohistochemical analysis. Out of the 23 clinical samples and 11 cell lines of plasma cell myeloma (PCM), none of the clinical samples and only 1 of 11 cell lines expressed CD79b immunohistologically, whereas non-neoplastic plasma cells in reactive hyperplastic lymph nodes exhibited loss of CD79b protein expression. This finding is quite different from our previous report on CD79a. Not only immunocytochemistry, but also RT-PCR and Western blot analysis of PCM cell lines gave identical results. Interestingly, we detected mRNA transcripts of CD79b in PCM cell lines, although protein translation was lacking. These findings suggest that expression of CD79b is downregulated in both plasma cells and plasma cell myeloma, and this process is possibly under post transcriptional regulation.",
keywords = "B-cell receptor, CD79a, CD79b, Plasma cell, Plasma cell myeloma",
author = "Xingang Huang and Katsuyoshi Takata and Yasuharu Sato and Takehiro Tanaka and Kouichi Ichimura and Maiko Tamura and Takashi Oka and Tadashi Yoshino",
year = "2011",
month = "3",
doi = "10.1111/j.1440-1827.2010.02634.x",
language = "English",
volume = "61",
pages = "122--129",
journal = "Pathology International",
issn = "1320-5463",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma

T2 - A possible post transcriptional regulation

AU - Huang, Xingang

AU - Takata, Katsuyoshi

AU - Sato, Yasuharu

AU - Tanaka, Takehiro

AU - Ichimura, Kouichi

AU - Tamura, Maiko

AU - Oka, Takashi

AU - Yoshino, Tadashi

PY - 2011/3

Y1 - 2011/3

N2 - The CD79 molecule, encoded by the CD79a and CD79b genes, is a signaling unit of the B-cell receptor complex, which transmits signals of B-cell activation, growth, and differentiation. They are B-cell-specific and expressed at most stages of B-cell development. Although plasma cells have been believed to lack these gene products, the regulation of CD79 expression in plasma cells is still controversial. In particular, the regulation of CD79b expression remains unclear. We sought to examine CD79b expression in normal and neoplastic plasma cells by immunohistochemical analysis. Out of the 23 clinical samples and 11 cell lines of plasma cell myeloma (PCM), none of the clinical samples and only 1 of 11 cell lines expressed CD79b immunohistologically, whereas non-neoplastic plasma cells in reactive hyperplastic lymph nodes exhibited loss of CD79b protein expression. This finding is quite different from our previous report on CD79a. Not only immunocytochemistry, but also RT-PCR and Western blot analysis of PCM cell lines gave identical results. Interestingly, we detected mRNA transcripts of CD79b in PCM cell lines, although protein translation was lacking. These findings suggest that expression of CD79b is downregulated in both plasma cells and plasma cell myeloma, and this process is possibly under post transcriptional regulation.

AB - The CD79 molecule, encoded by the CD79a and CD79b genes, is a signaling unit of the B-cell receptor complex, which transmits signals of B-cell activation, growth, and differentiation. They are B-cell-specific and expressed at most stages of B-cell development. Although plasma cells have been believed to lack these gene products, the regulation of CD79 expression in plasma cells is still controversial. In particular, the regulation of CD79b expression remains unclear. We sought to examine CD79b expression in normal and neoplastic plasma cells by immunohistochemical analysis. Out of the 23 clinical samples and 11 cell lines of plasma cell myeloma (PCM), none of the clinical samples and only 1 of 11 cell lines expressed CD79b immunohistologically, whereas non-neoplastic plasma cells in reactive hyperplastic lymph nodes exhibited loss of CD79b protein expression. This finding is quite different from our previous report on CD79a. Not only immunocytochemistry, but also RT-PCR and Western blot analysis of PCM cell lines gave identical results. Interestingly, we detected mRNA transcripts of CD79b in PCM cell lines, although protein translation was lacking. These findings suggest that expression of CD79b is downregulated in both plasma cells and plasma cell myeloma, and this process is possibly under post transcriptional regulation.

KW - B-cell receptor

KW - CD79a

KW - CD79b

KW - Plasma cell

KW - Plasma cell myeloma

UR - http://www.scopus.com/inward/record.url?scp=79952095089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952095089&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1827.2010.02634.x

DO - 10.1111/j.1440-1827.2010.02634.x

M3 - Article

C2 - 21355953

AN - SCOPUS:79952095089

VL - 61

SP - 122

EP - 129

JO - Pathology International

JF - Pathology International

SN - 1320-5463

IS - 3

ER -